With its higher affinity for lymphocytes in the tumor micro-environment compared to peripheral sites, it can inhibit CTLA-4 binding in peripheral blood and normal tissues, reducing the toxic side effects caused by the CTLA-4 inhibitors. Here, CTLA4 is linked to neoplasm.